Overview

A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Status:
Completed

Trial end date:
2000-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effects of the combination of all-trans retinoic acid in combination with one of two schedules of Bryostatin 1 in patients with myelodysplasia and acute myelogenous leukemia.

Phase:

Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Brigham and Women's Hospital

Treatments:

Bryostatin 1
Tretinoin